INC Research Releases New White Paper on How Clinical Innovation Leads to Improved Predictability and Efficiency for Drug Development Programs
(Thomson Reuters ONE) -
Paper offers innovative approaches to bringing drugs to market faster and
reducing development costs
Raleigh, N.C., June 18, 2013 - INC Research, LLC, a therapeutically focused
global clinical research organization (CRO) with a Trusted Process® for
delivering reliable results, today announced it has released a new white paper
titled, "Clinical Process Innovations for New Drug Development: Aligning
Clinical Trials with Development Needs." INC Research's paper explores the
challenges biopharms face in bringing new drugs to market and describes the
latest clinical innovations that are improving this process.
Biopharms are trapped between mounting pressure to reduce development costs and
the need to ensure better outcomes from clinical trials. Generics, lower
approval rates, and global testing requirements have increased drug development
costs. Yet, outcomes have remained uncertain in terms of both regulatory
approval and market acceptance, and large payers continue to exert downward
pressure on prices. However, recent guidance from the Federal Drug
Administration (FDA) and other regulatory bodies has paved the way for a more
risk-based approach to collecting and verifying trial data. The pharmaceutical
industry has also begun to embrace data analytics and reporting. Together these
factors are creating an opportunity to significantly reduce research and
development costs while providing more predictable outcomes.
"Despite continued R&D spending, approvals on compounds have declined or
remained flat. The spending problem is compounded by a slow drug development
process and a challenging regulatory environment," said INC Research CEO Jamie
Macdonald. "INC Research has been helping biopharms overcome these obstacles by
leveraging recent regulatory changes around the use of new data monitoring
techniques and advanced technology platforms to improve visibility into
outcomes. These innovations, combined with our data-driven Trusted Process®
methodology and extensive therapeutic expertise, are enabling biopharms to make
better use of their drug development capital."
INC's white paper discusses today's trends impacting clinical drug trials,
evolving challenges of conducting more efficient trials, and how best to
implement clinical process innovation within three key phases: planning,
engineering, execution and control.
As a leading CRO providing the full range of Phase I to IV clinical development
services on a worldwide scale, INC Research helps biopharms achieve greater
efficiency in bringing new drugs to market through a proven methodology that
supports consistent quality, reduced trial variability and complete transparency
for every phase of a development program. Using advanced data monitoring and
management systems, INC Research is able to provide a real-time status on all
projects and test sites. This active monitoring allows for the early detection
and response to emerging risks providing sponsors a high level of visibility and
predictability across their clinical trial programs.
To download a copy of "Clinical Process Innovations for New Drug Development:
Aligning Clinical Trials with Development Needs," visit
www.incresearch.com/Campaigns/201306-Whitepaper/clinical-process-
innovation.aspx.
About INC Research
INC Research is a therapeutically focused clinical research organization with a
high-performance reputation for conducting global clinical development programs
of the highest integrity. Pharmaceutical and biotechnology companies look to us
for a complete range of customized Phase I to IV programs in all therapeutic
areas and patient populations. Our Trusted Process® methodology and therapeutic
foresight lead customers to better-informed product development decisions, while
our solid site relationships are a critical success factor in delivering
clinical trial results on time and on budget. INC was ranked "Top CRO" by sites
worldwide in the 2013 CenterWatch Global Investigative Site Relationship Survey.
INC Research is headquartered in Raleigh, NC. For more information, please
visit www.incresearch.com or follow us at (at)inc_research.
Contact: Lori Dorer, Media +1 (513) 345-1685
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: INC RESEARCH, LLC via Thomson Reuters ONE
[HUG#1710374]
Unternehmensinformation / Kurzprofil:
Datum: 18.06.2013 - 20:45 Uhr
Sprache: Deutsch
News-ID 271057
Anzahl Zeichen: 5189
contact information:
Town:
Raleigh
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 235 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"INC Research Releases New White Paper on How Clinical Innovation Leads to Improved Predictability and Efficiency for Drug Development Programs"
steht unter der journalistisch-redaktionellen Verantwortung von
INC RESEARCH, LLC (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
